CLN2疾病:当前的理解,挑战和未来的方向
Maria Shock1, Elisa Nigro2, Elizabeth J Donner2
1Division of Neurology, Department of Paediatrics, McMaster University, Hamilton, Ontario, Canada.
Journal of child neurology
|September 18, 2025
概括
神经神经质脂症类型2 (CLN2) 疾病是一种罕见的神经退行性疾病. 早期诊断和酶替代疗法至关重要,因为治疗不能逆转现有的损伤,但可以改变疾病的进程.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 儿科 儿科 儿科
背景情况:
- 神经神经质脂症2型 (CLN2) 疾病是一种罕见的,致命的神经退行性儿童疾病.
- 语言回归,运动衰退,发作和视力丧失的快速进展是其特征.
- 酶替代疗法 (ERT) 已成为一种变革性的治疗方法,需要早期诊断.
研究的目的:
- 审查目前对CLN2疾病的理解.
- 专注于早期临床表现,诊断挑战和治疗进展.
- 突出ERT的影响以及基因疗法等未来治疗前景.
主要方法:
- 关于CLN2疾病的文献评论.
- 对临床表现,诊断工具和治疗结果的分析.
- 探索新兴疗法和全球接入的挑战.
主要成果:
- 早期的临床症状可能是微妙的,导致诊断延迟.
- ERT显著改变了疾病的发展轨迹,但无法逆转已有的损害.
- 基因疗法显示出希望,但在有效性和交付方面面临挑战.
结论:
- 早期识别和介入ERT对于管理CLN2疾病至关重要.
- 解决全球获取差异和优化治疗策略至关重要.
- 需要对基因疗法和生物标志物的持续研究才能找到潜在的治疗方法.
相关概念视频
Cystic Fibrosis: Pathogenesis
726
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
726
Cystic Fibrosis: Management
476
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
476
Chronic Kidney Disease II: Clinical Manifestations
557
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
557
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
474
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
474
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
364
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
364


